4.7 Article

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)

Journal

RHEUMATOLOGY
Volume 49, Issue 2, Pages 289-294

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kep354

Keywords

Rheumatoid arthritis; Anti-TNF therapy; Decision making; Patient empowerment

Categories

Funding

  1. Schering-Plough

Ask authors/readers for more resources

Objective. To identify the determinants of anti-TNF-naive patients' preferences for the route of administration of anti-TNF agents. Methods. The study was carried out in 50 Italian rheumatology centres (802 patients). All patients completed a 31-item questionnaire addressing their perceptions of current treatment and the preferences for treatment with anti-TNF agents. Statistical methods included analysis of variance (ANOVA), t-test and chi-square test. Results. The response rate to the questionnaire was 97.6%. At the time of the survey, 310 (39.9%) patients were dissatisfied with current treatments, owing to inefficacy, side effects and inconvenience of administration. The i.v. and s.c. routes of administration were preferred by 50.2 and 49.8%, respectively. No significant difference was found in patients by gender, age, RA duration or number of drugs used. Reasons for the choice of i.v. administration were the safety of treatment at the hospital and the reassuring effect of physician presence. The s.c. administration was chosen for the convenience of treatment and in particular for home treatment. Patients dissatisfied with current therapy due to side effects preferred s.c. administration (P = 0.029), whereas patients choosing the i.v. route had slightly higher scores on 'today pain' (P = 0.047) and 'articular pain' (P = 0.023) of the Rheumatoid Arthritis Disease Activity Index (RADAI). Conclusions. Both i.v. and s.c. treatments were well accepted by patients. However, treatment choice has to be discussed with patients, as individual preference seems to be determined by personal attitudes towards safety and convenience, by past experience and by the perception of current disease status.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort

Ennio G. Favalli, Andrea Becciolini, Antonio Carletto, Fabrizio Conti, Giorgio Amato, Enrico Fusaro, Luca Quartuccio, Colin Gerard Egan, Andrea Lo Monaco, Maurizio Benucci, Fausto Salaffi, Angelo Semeraro, Simone Parisi, Fulvia Ceccarelli, Ilaria Piazza, Rosario Foti

RHEUMATOLOGY INTERNATIONAL (2020)

Review Rheumatology

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review

Xenofon Baraliakos, Lianne S. Gensler, Salvatore D'Angelo, Florenzo Iannone, Ennio G. Favalli, Natasha de Peyrecave, Simone E. Auteri, Roberto Caporali

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)

Letter Rheumatology

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Ennio Giulio Favalli, Francesca Ingegnoli, Rolando Cimaz, Roberto Caporali

ANNALS OF THE RHEUMATIC DISEASES (2021)

Letter Rheumatology

Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis

Serena Bugatti, Ludovico De Stefano, Ennio Giulio Favalli, Roberto Caporali, Carlomaurizio Montecucco

ANNALS OF THE RHEUMATIC DISEASES (2022)

Letter Rheumatology

Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients

Ennio Giulio Favalli, Orazio De Lucia, Martina Biggioggero, Nicoletta Del Papa, Roberto Caporali

ANNALS OF THE RHEUMATIC DISEASES (2021)

Article Immunology

Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study

Piercarlo Sarzi-Puttini, Daniela Marotto, Roberto Caporali, Carlo Maurizio Montecucco, Ennio Giulio Favalli, Franco Franceschini, Michela Fredi, Silvia Balduzzi, Chiara Bazzani, Sara Bongiovanni, Valeria Giorgi, Alberto Batticciotto, Antonella Cappelli, Patrizia Balzarini, Lorenzo Dagna, Silvia Sartorelli, Viviana Ravagnani, Silvia Tamanini, Sonia Farah, Paola Faggioli, Laura Castelnovo, Alfredo Maria Lurati, Massimo Galli, Fausto Salaffi

Summary: The study found that rheumatic patients have a similar risk of contracting COVID-19 as the general population, but age, disease duration, and number of co-morbidities are associated with an increased risk of a severe form of the disease. Immunosuppressants drugs seem to not effectively represent a risk factor for COVID-19.

JOURNAL OF AUTOIMMUNITY (2021)

Letter Rheumatology

Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy

Francesca Ingegnoli, Gilberto Cincinelli, Angela Flavia Luppino, Ennio Giulio Favalli, Annalisa Orenti, Patrizia Boracchi, Roberto Caporali

ANNALS OF THE RHEUMATIC DISEASES (2021)

Review Immunology

Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic

Ennio Giulio Favalli, Gabriella Maioli, Martina Biggioggero, Roberto Caporali

Summary: The COVID-19 pandemic poses challenges for managing patients with rheumatoid arthritis (RA) due to their increased susceptibility to infection events. Disease-modifying anti-rheumatic drugs (DMARDs) have potential effects on patients' vulnerability to COVID-19, and international guidelines emphasize the importance of focusing on RA patients in this context.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2021)

Article Pharmacology & Pharmacy

Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights

Maria Gabriella Raimondo, Martina Biggioggero, Lavinia Agra Coletto, Andreas Ramming, Roberto Caporali, Ennio Giulio Favalli

Summary: Rheumatoid arthritis is a chronic autoimmune disease with a modified natural course due to the development of new therapeutic approaches. Filgotinib, a Janus kinase1 selective inhibitor, has shown comparable clinical efficacy to biologic treatments for active RA with an acceptable safety profile. Real-life data and head-to-head clinical trials are needed to confirm its efficacy and safety.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

Article Rheumatology

Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis

Serena Bugatti, Ludovico De Stefano, Bernardo D'Onofrio, Andrea Nicrosini, Eleonora Mauric, Michele di Lernia, Garifallia Sakellariou, Ennio Giulio Favalli, Antonio Manzo, Roberto Caporali, Carlomaurizio Montecucco

Summary: This study found that in the early stages of rheumatoid arthritis, particularly in patients who test positive for autoantibodies, inflammatory markers are directly correlated with the Patient Global Assessment. However, in patients with established rheumatoid arthritis, there is no independent correlation between inflammatory markers and the Patient Global Assessment, regardless of disease activity and autoantibody status.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Review Pharmacology & Pharmacy

Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis

Gabriella Maioli, Roberto Caporali, Ennio Giulio Favalli

Summary: This article discusses the role of the IL-6 pathway in the pathogenesis of rheumatoid arthritis and the pharmacologic properties of the IL-6 inhibitor sarilumab. Clinical trials have confirmed the efficacy and safety of sarilumab in treating RA, making it a potential alternative for patients intolerant to conventional disease-modifying drugs.

EXPERT OPINION ON DRUG DISCOVERY (2022)

Article Rheumatology

Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E. G. Favalli, R. Caporali

Summary: The objective of this study was to evaluate the survival rates of biological disease-modifying anti-rheumatic drugs (bDMARDs) in patients with psoriatic arthritis (PsA), comparing tumor necrosis factor inhibitors (TNFi) and non-TNFi retention rates. The study found that the TNFi group had a younger age at the start of therapy and a lower proportion of patients with skin psoriasis. Survival analysis showed no significant differences between TNFi and non-TNFi groups. Cox regression analysis identified fibromyalgia as a predictor of drug failure and first-line bDMARDs as a protective factor.

REUMATISMO (2023)

Article Rheumatology

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

Ennio Giulio Favalli, Serena Bugatti, Catherine Klersy, Martina Biggioggero, Silvia Rossi, Orazio De Lucia, Francesca Bobbio-Pallavicini, Antonella Murgo, Silvia Balduzzi, Roberto Caporali, Carlomaurizio Montecucco

ARTHRITIS RESEARCH & THERAPY (2020)

Article Rheumatology

Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients

E. G. Favalli, F. Conti, C. Selmi, F. Iannone, R. Bucci, F. D'Onofrio, G. Carlino, L. Santo, A. Semeraro, C. Zuccaro, S. D'Angelo, F. Atzeni, F. Marino, S. Monti, G. M. Guidelli, F. R. Spinelli, M. Biggioggero, R. Caporali

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2020)

No Data Available